Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus (Q47909323)

6 February 2018

title

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus (English)

1 reference

6 February 2018

1 reference

Fonseca VA

1 reference

6 February 2018

Reynolds T

1 reference

6 February 2018

Hemphill D

1 reference

6 February 2018

Randolph C

1 reference

6 February 2018

Wall J

1 reference

6 February 2018

Valiquet TR

1 reference

6 February 2018

Graveline J

1 reference

6 February 2018

Fink LM

1 reference

6 February 2018

publication date

1 July 1998

1 reference

6 February 2018

Journal of Diabetes and its Complications

published in

1 reference

6 February 2018

volume

1 reference

6 February 2018

issue

1 reference

6 February 2018

page(s)

181-186

1 reference

6 February 2018

Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Endothelial markers in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

Dietary regulation of fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2897%2900109-8

7 January 2021

10.1016/S1056-8727(97)00109-8

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018